Skip to main content
SERA logo

SERA · Sera Prognostics, Inc.

Track SERA — free
$1.89 -0.02 (-1.05%) At close · Nov 19
Market Cap
$75.16M
Shares
39.77M
Volume · Nov 19 46.46K Avg daily vol (3M) 26.7K

Price & Indicators

 

Key stats

Close
$1.89
Open
$1.84
Day range
$1.80–1.94
52-week closing range
$1.59–3.69
Average volume, 30 days
34K
Short interest
220K · 0.6% of shares · 9.1 days
Short volume, last session
59%
Last earnings
Nov 4, 2026
Latest filing
10-Q · Nov 4
Price history
Jul 2021 to Nov 2026

Up next

Mar 17, 2027 Est · unconfirmed · in 17 wks

Latest documents

2026
Nov 4
Earnings call
Test volume rises approximately fivefold amid Medicaid expansion

SERA reported test volume increased approximately fivefold from the first quarter of 2026, while Illinois and Florida Medicaid coverage supports nearly 7 million covered lives and approximately 140,000 annual births. Operating expenses fell 11% sequentially; cash reached $72.8 million.

5 source passages
# Earnings Call Transcript - SERA Q3 FY2026 Compared to the first quarter of this year, the number of physicians ordering preterm nearly tripled, while test volume increased approximately fivefold. These two states represent approximately 7 million newly covered lives, encompassing approximately 140,000 Medicaid births per year. From an expense perspective, we saw total operating expenses decline by 11% on a sequential basis, based upon our targeted cost-saving efforts initiated following our fiscal second quarter. We ended the quarter with $72.8 million in cash and cash equivalents. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
PreTRM Medicaid coverage expands as losses widen

Sera Prognostics said nine-month net loss increased to $25.6 million from $24.0 million, while cash, cash equivalents and available-for-sale securities totaled $72.8 million; PreTRM gained Florida and Illinois Medicaid coverage, and expected cash funding extends into 2029.

Revenue $42K ▲ 162.5% Net loss $8.05M Diluted EPS -$0.16
Read from the MD&A section
5 source passages
Our net losses were $8.1 million and $7.8 million for the three months ended September 30, 2026 and 2025, respectively, and $25.6 million and $24.0 million for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, we had aggregate cash, cash equivalents, and available-for-sale securities of $72.8 million, and an accumulated deficit of $337.3 million. Following the passage of Florida’s biomarker testing legislation (Chapter 2024-249) in 2024, the Florida Agency for Health Care Administration has added the PreTRM test’s PLA code 0247U to its covered biomarker test list and to the Florida Medicaid laboratory fee schedule. After the enactment of Illinois legislation establishing Medicaid coverage for the PreTRM test, the test’s PLA code 0247U was added to the Illinois Medicaid fee schedule at $525, with no prior authorization required. With this new cost structure, we expect that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into 2029. Open the document at this passage
Nov 4
Current report 8-K
PreTRM volume rises 54% as Florida adds Medicaid coverage

Sera Prognostics reported third-quarter PreTRM test volume up 54% sequentially and revenue of $42,000, up 163% year over year. Florida Medicaid coverage expanded covered lives to approximately 7 million patients.

Financial results
4 source passages
PreTRM test volumes increased 54% sequentially and almost five-fold from the 1Q26 following the PRIME study publication early this year and recent commercial leadership team hires. Total PreTRM test revenue in the quarter was $42,000 representing a 163% increase on a year-over-year basis. This brings total covered Medicaid lives to approximately 7 million patients. Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter ended September 30, 2026. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$96,000
Trailing 12 months
Net income (TTM)
−$33.47M
Trailing 12 months
Revenue growth YoY
+162.5%
Year over year
Operating margin
-38,755.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-38.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$44.09M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.6%
Year over year · more shares
Price change (1Y)
-40.9%
Trailing year
Short interest
0.6%
Latest settlement · 9.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. Commercial momentum accelerated: test volume rose 54% sequentially, ordering providers increased 34%, revenue rose 163% year over year, and Florida expanded Medicaid coverage. However, lower ASPs hurt revenue, the company remains loss-making and cash-consuming, physician adoption can take 12 to 18 months, and additional capital may be needed.

Bullish
  • + Florida and Illinois Medicaid coverage supports approximately 7 million covered lives and 140,000 annual births.
  • + PreTRM test volume increased 54% sequentially and almost five-fold from the first quarter of 2026.
  • + Ordering healthcare providers increased 34% sequentially and approximately three-fold from the first quarter of 2026.
  • + Total PreTRM test revenue increased 163% year over year.
  • + PRIME subgroup analysis showed PreTRM-guided care reduced NICU admissions among first-time mothers by 22%.
  • + The company launched a fourth payer partnership program and discussed a large multi-state payer pilot planned for fiscal 2027.
Bearish
  • − Lower average selling prices negatively affected revenue because of a higher mix of low or non-reimbursed tests.
  • − The company reported a third-quarter net loss.
  • − Third-quarter cash burn from operations was $7.3 million.
  • − Nine-month net cash used in operating activities was negative.
  • − Physician adoption generally takes 12 to 18 months, delaying meaningful utilization of expanded ordering.
  • − Net losses, cash generation, and the potential need to raise more capital are among the stated risks.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg −7%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 14%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −7%
trailing
6-month return −14%
trailing
YTD return −36%
this year
Relative strength −8%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+2% holders QoQ · +6 funds added
Insider flow Distributing
Net -$79.6K over 90 days · 100% sells
Short interest Falling
0.55% of shares out · ▼ -1.3% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
48 holders — mid 3-yr range
Squeeze score 44
elevated · 0–100
Fundamentals
Strong
Revenue growth +5%
Y/Y
EPS growth +32%
Y/Y
Free cash flow $-26.3M
Balance sheet $3.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 67%
annualized · 1-yr
Max drawdown −57%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
14% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+2% holders QoQ · +6 funds added
Insider flow Distributing
Net -$79.6K over 90 days · 100% sells
Short interest Falling
0.55% of shares out · ▼ -1.3% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
48 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 14% Range high $4
vs 200-day avg -8% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
cash, cash equivalents and available-for-sale securities $80.3M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SERA
Sera Prognostics, Inc.
this stock
$75.16M -35.9% +5.2% — 0.6%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
48
% held
49.7%
Net QoQ
+2.7M sh
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
22
View
Short & Settlement
Short Interest Falling
Shares short
219.8K
Days to cover
9.1d
Change
-3.0K sh
View
Short Volume
Short vol %
59%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
90
Value
$185
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
38.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$79.6K
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$81.0K
Net income (FY)
$-31.9M
EPS diluted
$-0.67
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
19

Sera Prognostics said nine-month net loss increased to $25.6 million from $24.0 million, while cash, cash equivalents and available-for-sale securities totaled $72.8 million; PreTRM gained Florida and Illinois Medicaid coverage, and expected cash funding extends into 2029.

View
Proposed Sales
Value
$16.3K
Shares
8.0K
Filed
Oct 13, 2026
View
Exempt Offerings
Offering
$100.3M
Filed
May 11, 2021
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
SERA PROGNOSTICS REPORTS THIRD QU…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
SERA -4.6% -7.4% -13.7% -7.4% -35.9%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +0.9% -1.1% -8.1% -2.1% -40.9%
Key facts CIK 1534969 CUSIP 81749D107 13F (30d) 50 filings 43 filers Visit website Investor relations